English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17939/22958 (78%)
Visitors : 7387248      Online Users : 134
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24902


    Title: Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC
    Authors: Cheng, FJ;Chen, CH;Tsai, WC;Wang, BW;Yu, MC;Hsia, TC;Wei, YL;Hsiao, YC;Hu, DW;Ho, CY;Li, TS;Wu, CY;Chou, WY;Yu, YL;Tang, CH;Chen, CY;Chen, CM;Hsu, JL;Chen, HF;Chen, Y;Tu, CY;Hung, MC;Huang, WC
    Date: 2021
    Issue Date: 2022-08-09T08:09:51Z (UTC)
    Publisher: SPRINGERNATURE
    ISSN: 0950-9232
    Abstract: Smoker patients with non-small cell lung cancer (NSCLC) have poorer prognosis and survival than those without smoking history. However, the mechanisms underlying the low response rate of those patients to EGFR tyrosine kinase inhibitors (TKIs) are not well understood. Here we report that exposure to cigarette smoke extract enhances glycolysis and attenuates AMP-activated protein kinase (AMPK)-dependent inhibition of mTOR; this in turn reduces the sensitivity of NSCLC cells with wild-type EGFR (EGFR(WT)) to EGFR TKI by repressing expression of liver kinase B1 (LKB1), a master kinase of the AMPK subfamily, via CpG island methylation. In addition, LKB1 expression is correlated positively with sensitivity to TKI in patients with NSCLC. Moreover, combined treatment of EGFR TKI with AMPK activators synergistically increases EGFR TKI sensitivity. Collectively, the current study suggests that LKB1 may serve as a marker to predict EGFR TKI sensitivity in smokers with NSCLC carrying EGFR(WT) and that the combination of EGFR TKI and AMPK activator may be a potentially effective therapeutic strategy against NSCLC with EGFR(WT).
    URI: http://dx.doi.org/10.1038/s41388-020-01597-1
    https://www.webofscience.com/wos/woscc/full-record/WOS:000599788200001
    https://ir.csmu.edu.tw:8080/handle/310902500/24902
    Relation: ONCOGENE ,2021 ,v40 ,issue 6 ,p1162-1175
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML253View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback